|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:FASN-ESR1 (FusionGDB2 ID:29348) |
Fusion Gene Summary for FASN-ESR1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: FASN-ESR1 | Fusion gene ID: 29348 | Hgene | Tgene | Gene symbol | FASN | ESR1 | Gene ID | 2194 | 2099 |
| Gene name | fatty acid synthase | estrogen receptor 1 | |
| Synonyms | FAS|OA-519|SDR27X1 | ER|ESR|ESRA|ESTRR|Era|NR3A1 | |
| Cytomap | 17q25.3 | 6q25.1-q25.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | fatty acid synthaseshort chain dehydrogenase/reductase family 27X, member 1 | estrogen receptorE2 receptor alphaER-alphaestradiol receptorestrogen nuclear receptor alphaestrogen receptor alpha E1-E2-1-2estrogen receptor alpha E1-N2-E2-1-2nuclear receptor subfamily 3 group A member 1oestrogen receptor alpha | |
| Modification date | 20200329 | 20200329 | |
| UniProtAcc | P49327 | P03372 | |
| Ensembl transtripts involved in fusion gene | ENST00000306749, ENST00000579758, | ENST00000440973, ENST00000338799, ENST00000456483, ENST00000443427, ENST00000206249, ENST00000406599, ENST00000427531, ENST00000482101, | |
| Fusion gene scores | * DoF score | 11 X 12 X 6=792 | 10 X 10 X 6=600 |
| # samples | 11 | 12 | |
| ** MAII score | log2(11/792*10)=-2.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/600*10)=-2.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: FASN [Title/Abstract] AND ESR1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | FASN(80046335)-ESR1(152265458), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ESR1 | GO:0006366 | transcription by RNA polymerase II | 15831516 |
| Tgene | ESR1 | GO:0010629 | negative regulation of gene expression | 21695196 |
| Tgene | ESR1 | GO:0030520 | intracellular estrogen receptor signaling pathway | 9841876 |
| Tgene | ESR1 | GO:0032355 | response to estradiol | 15304487 |
| Tgene | ESR1 | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 7651415|16043358 |
| Tgene | ESR1 | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 10816575 |
| Tgene | ESR1 | GO:0043627 | response to estrogen | 11581164 |
| Tgene | ESR1 | GO:0045893 | positive regulation of transcription, DNA-templated | 9841876|20074560 |
| Tgene | ESR1 | GO:0045899 | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly | 9841876 |
| Tgene | ESR1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11544182|12047722|15345745|15831516|18563714 |
| Tgene | ESR1 | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 9328340|10681512 |
| Tgene | ESR1 | GO:0071392 | cellular response to estradiol stimulus | 15831516 |
| Fusion gene breakpoints across FASN (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ESR1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS5.0 | N/A | AF172068 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| ChiTaRS5.0 | N/A | AF172069 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
Top |
Fusion Gene ORF analysis for FASN-ESR1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3CDS | ENST00000306749 | ENST00000440973 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-3CDS | ENST00000306749 | ENST00000338799 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000306749 | ENST00000456483 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000306749 | ENST00000443427 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000306749 | ENST00000206249 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000306749 | ENST00000406599 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000306749 | ENST00000427531 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-3UTR | ENST00000306749 | ENST00000482101 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-3CDS | ENST00000579758 | ENST00000440973 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-3CDS | ENST00000579758 | ENST00000338799 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000579758 | ENST00000456483 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000579758 | ENST00000443427 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000579758 | ENST00000206249 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000579758 | ENST00000406599 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-intron | ENST00000579758 | ENST00000427531 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| intron-3UTR | ENST00000579758 | ENST00000482101 | FASN | chr17 | 80046335 | - | ESR1 | chr6 | 152265458 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for FASN-ESR1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for FASN-ESR1 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| FASN | ESR1 |
| FUNCTION: Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain. {ECO:0000269|PubMed:16215233, ECO:0000269|PubMed:16969344, ECO:0000269|PubMed:26851298, ECO:0000269|PubMed:7567999, ECO:0000269|PubMed:8962082, ECO:0000269|PubMed:9356448}. | FUNCTION: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626, ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875, ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358, ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779, ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611, ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956, ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for FASN-ESR1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for FASN-ESR1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for FASN-ESR1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | FASN | P49327 | DB01083 | Orlistat | Inhibitor | Small molecule | Approved|Investigational |
| Hgene | FASN | P49327 | DB01083 | Orlistat | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved |
Top |
Related Diseases for FASN-ESR1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | FASN | C0025202 | melanoma | 3 | CTD_human |
| Hgene | FASN | C2239176 | Liver carcinoma | 3 | CTD_human |
| Hgene | FASN | C0006142 | Malignant neoplasm of breast | 2 | CTD_human |
| Hgene | FASN | C0678222 | Breast Carcinoma | 2 | CTD_human |
| Hgene | FASN | C1257931 | Mammary Neoplasms, Human | 2 | CTD_human |
| Hgene | FASN | C1458155 | Mammary Neoplasms | 2 | CTD_human |
| Hgene | FASN | C4704874 | Mammary Carcinoma, Human | 2 | CTD_human |
| Hgene | FASN | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| Hgene | FASN | C0007193 | Cardiomyopathy, Dilated | 1 | CTD_human |
| Hgene | FASN | C0007194 | Hypertrophic Cardiomyopathy | 1 | CTD_human |
| Hgene | FASN | C0018801 | Heart failure | 1 | CTD_human |
| Hgene | FASN | C0018802 | Congestive heart failure | 1 | CTD_human |
| Hgene | FASN | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| Hgene | FASN | C0020796 | Profound Mental Retardation | 1 | CTD_human |
| Hgene | FASN | C0022661 | Kidney Failure, Chronic | 1 | CTD_human |
| Hgene | FASN | C0023212 | Left-Sided Heart Failure | 1 | CTD_human |
| Hgene | FASN | C0023827 | liposarcoma | 1 | CTD_human |
| Hgene | FASN | C0025363 | Mental Retardation, Psychosocial | 1 | CTD_human |
| Hgene | FASN | C0027651 | Neoplasms | 1 | CTD_human |
| Hgene | FASN | C0028754 | Obesity | 1 | CTD_human |
| Hgene | FASN | C0086132 | Depressive Symptoms | 1 | PSYGENET |
| Hgene | FASN | C0086692 | Benign Neoplasm | 1 | CTD_human |
| Hgene | FASN | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Hgene | FASN | C0205824 | Liposarcoma, Dedifferentiated | 1 | CTD_human |
| Hgene | FASN | C0205825 | Liposarcoma, Pleomorphic | 1 | CTD_human |
| Hgene | FASN | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human |
| Hgene | FASN | C0279626 | Squamous cell carcinoma of esophagus | 1 | CTD_human |
| Hgene | FASN | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| Hgene | FASN | C0917816 | Mental deficiency | 1 | CTD_human |
| Hgene | FASN | C0919267 | ovarian neoplasm | 1 | CTD_human |
| Hgene | FASN | C0948089 | Acute Coronary Syndrome | 1 | CTD_human |
| Hgene | FASN | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human |
| Hgene | FASN | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| Hgene | FASN | C1370889 | Liposarcoma, well differentiated | 1 | CTD_human |
| Hgene | FASN | C1449563 | Cardiomyopathy, Familial Idiopathic | 1 | CTD_human |
| Hgene | FASN | C1959583 | Myocardial Failure | 1 | CTD_human |
| Hgene | FASN | C1961112 | Heart Decompensation | 1 | CTD_human |
| Hgene | FASN | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| Hgene | FASN | C3714756 | Intellectual Disability | 1 | CTD_human |
| Hgene | FASN | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Hgene | FASN | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
| Hgene | FASN | C4551472 | Hypertrophic obstructive cardiomyopathy | 1 | CTD_human |
| Tgene | ESR1 | C0006142 | Malignant neoplasm of breast | 14 | CGI;CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | ESR1 | C0678222 | Breast Carcinoma | 14 | CGI;CTD_human |
| Tgene | ESR1 | C1257931 | Mammary Neoplasms, Human | 14 | CTD_human |
| Tgene | ESR1 | C1458155 | Mammary Neoplasms | 14 | CTD_human |
| Tgene | ESR1 | C4704874 | Mammary Carcinoma, Human | 14 | CTD_human |
| Tgene | ESR1 | C0005586 | Bipolar Disorder | 5 | PSYGENET |
| Tgene | ESR1 | C0011570 | Mental Depression | 5 | PSYGENET |
| Tgene | ESR1 | C0011581 | Depressive disorder | 5 | PSYGENET |
| Tgene | ESR1 | C0036341 | Schizophrenia | 5 | PSYGENET |
| Tgene | ESR1 | C0525045 | Mood Disorders | 4 | PSYGENET |
| Tgene | ESR1 | C3809250 | ESTROGEN RESISTANCE | 3 | GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | ESR1 | C0001418 | Adenocarcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0007097 | Carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Tgene | ESR1 | C0010054 | Coronary Arteriosclerosis | 2 | CTD_human |
| Tgene | ESR1 | C0021364 | Male infertility | 2 | CTD_human |
| Tgene | ESR1 | C0024121 | Lung Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0024667 | Animal Mammary Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0025500 | Mesothelioma | 2 | CTD_human |
| Tgene | ESR1 | C0027626 | Neoplasm Invasiveness | 2 | CTD_human |
| Tgene | ESR1 | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0205641 | Adenocarcinoma, Basal Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205642 | Adenocarcinoma, Oxyphilic | 2 | CTD_human |
| Tgene | ESR1 | C0205643 | Carcinoma, Cribriform | 2 | CTD_human |
| Tgene | ESR1 | C0205644 | Carcinoma, Granular Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205645 | Adenocarcinoma, Tubular | 2 | CTD_human |
| Tgene | ESR1 | C0205696 | Anaplastic carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0205697 | Carcinoma, Spindle-Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205698 | Undifferentiated carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0205699 | Carcinomatosis | 2 | CTD_human |
| Tgene | ESR1 | C0242379 | Malignant neoplasm of lung | 2 | CTD_human |
| Tgene | ESR1 | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
| Tgene | ESR1 | C0848676 | Subfertility, Male | 2 | CTD_human |
| Tgene | ESR1 | C0917731 | Male sterility | 2 | CTD_human |
| Tgene | ESR1 | C1257925 | Mammary Carcinoma, Animal | 2 | CTD_human |
| Tgene | ESR1 | C1956346 | Coronary Artery Disease | 2 | CTD_human |
| Tgene | ESR1 | C2239176 | Liver carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| Tgene | ESR1 | C0004114 | Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0004153 | Atherosclerosis | 1 | CTD_human |
| Tgene | ESR1 | C0005684 | Malignant neoplasm of urinary bladder | 1 | CTD_human |
| Tgene | ESR1 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
| Tgene | ESR1 | C0005940 | Bone Diseases | 1 | CTD_human |
| Tgene | ESR1 | C0005944 | Metabolic Bone Disorder | 1 | CTD_human |
| Tgene | ESR1 | C0007852 | Cervical Migraine Syndrome | 1 | CTD_human |
| Tgene | ESR1 | C0011265 | Presenile dementia | 1 | CTD_human |
| Tgene | ESR1 | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
| Tgene | ESR1 | C0017658 | Glomerulonephritis | 1 | CTD_human |
| Tgene | ESR1 | C0018984 | Hemicrania migraine | 1 | CTD_human |
| Tgene | ESR1 | C0021361 | Female infertility | 1 | CTD_human |
| Tgene | ESR1 | C0023267 | Fibroid Tumor | 1 | CTD_human |
| Tgene | ESR1 | C0023418 | leukemia | 1 | CTD_human |
| Tgene | ESR1 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Tgene | ESR1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| Tgene | ESR1 | C0024809 | Marijuana Abuse | 1 | PSYGENET |
| Tgene | ESR1 | C0026858 | Musculoskeletal Pain | 1 | CTD_human |
| Tgene | ESR1 | C0027051 | Myocardial Infarction | 1 | CTD_human |
| Tgene | ESR1 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Tgene | ESR1 | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| Tgene | ESR1 | C0027819 | Neuroblastoma | 1 | CTD_human |
| Tgene | ESR1 | C0028754 | Obesity | 1 | CTD_human |
| Tgene | ESR1 | C0028960 | Oligospermia | 1 | CTD_human |
| Tgene | ESR1 | C0029453 | Osteopenia | 1 | CTD_human |
| Tgene | ESR1 | C0033937 | Psychoses, Drug | 1 | CTD_human |
| Tgene | ESR1 | C0033941 | Psychoses, Substance-Induced | 1 | CTD_human |
| Tgene | ESR1 | C0036939 | Shared Paranoid Disorder | 1 | PSYGENET |
| Tgene | ESR1 | C0038279 | Sterility, Postpartum | 1 | CTD_human |
| Tgene | ESR1 | C0042133 | Uterine Fibroids | 1 | CTD_human |
| Tgene | ESR1 | C0149931 | Migraine Disorders | 1 | CTD_human |
| Tgene | ESR1 | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0235874 | Disease Exacerbation | 1 | CTD_human |
| Tgene | ESR1 | C0270858 | Abdominal Migraine | 1 | CTD_human |
| Tgene | ESR1 | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| Tgene | ESR1 | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0282612 | Prostatic Intraepithelial Neoplasias | 1 | CTD_human |
| Tgene | ESR1 | C0334579 | Anaplastic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334583 | Pilocytic Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0338489 | Status Migrainosus | 1 | CTD_human |
| Tgene | ESR1 | C0341869 | Subfertility, Female | 1 | CTD_human |
| Tgene | ESR1 | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| Tgene | ESR1 | C0476089 | Endometrial Carcinoma | 1 | CGI;CTD_human |
| Tgene | ESR1 | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| Tgene | ESR1 | C0521664 | Acute Confusional Migraine | 1 | CTD_human |
| Tgene | ESR1 | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| Tgene | ESR1 | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0700438 | Sick Headaches | 1 | CTD_human |
| Tgene | ESR1 | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| Tgene | ESR1 | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| Tgene | ESR1 | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0917730 | Female sterility | 1 | CTD_human |
| Tgene | ESR1 | C1563937 | Atherogenesis | 1 | CTD_human |
| Tgene | ESR1 | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C1704377 | Bright Disease | 1 | CTD_human |
| Tgene | ESR1 | C1720887 | Female Urogenital Diseases | 1 | CTD_human |
| Tgene | ESR1 | C1800706 | Idiopathic Pulmonary Fibrosis | 1 | CTD_human |
| Tgene | ESR1 | C4721508 | Hamman-Rich Disease | 1 | CTD_human |
| Tgene | ESR1 | C4721509 | Usual Interstitial Pneumonia | 1 | CTD_human |
| Tgene | ESR1 | C4721952 | Familial Idiopathic Pulmonary Fibrosis | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies